Clinical Trial Update: A Phase I/II Study to Evaluate the Safety and Immunogenicity of GC3111B in Healthy Adults [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial entry evaluating the safety and immunogenicity of GC3111B in healthy adults, with recruitment ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diphtheria
• Pertussis
• Tetanus

Drugs mentioned

• GC3111B

Snippet

Sponsor: GC Biopharma Corp | Conditions: Tetanus-diphtheria-acellular Pertussis (Tdap) | Phase 1, Phase 2 | Status: RECRUITING